[go: up one dir, main page]

DE69817611D1 - 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate - Google Patents

2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate

Info

Publication number
DE69817611D1
DE69817611D1 DE69817611T DE69817611T DE69817611D1 DE 69817611 D1 DE69817611 D1 DE 69817611D1 DE 69817611 T DE69817611 T DE 69817611T DE 69817611 T DE69817611 T DE 69817611T DE 69817611 D1 DE69817611 D1 DE 69817611D1
Authority
DE
Germany
Prior art keywords
oxodihydropurin
intermediates
aryl
derivatives
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69817611T
Other languages
English (en)
Other versions
DE69817611T2 (de
Inventor
Teruya Murata
Kaoru Masumoto
Katsunori Kondo
Kiyoshi Furukawa
Makoto Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Publication of DE69817611D1 publication Critical patent/DE69817611D1/de
Application granted granted Critical
Publication of DE69817611T2 publication Critical patent/DE69817611T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69817611T 1997-12-03 1998-11-26 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate Expired - Fee Related DE69817611T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03
JP35000097 1997-12-03
PCT/JP1998/005320 WO1999028320A1 (en) 1997-12-03 1998-11-26 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof

Publications (2)

Publication Number Publication Date
DE69817611D1 true DE69817611D1 (de) 2003-10-02
DE69817611T2 DE69817611T2 (de) 2004-02-26

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69817611T Expired - Fee Related DE69817611T2 (de) 1997-12-03 1998-11-26 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate

Country Status (26)

Country Link
US (1) US6372740B1 (de)
EP (1) EP1036794B1 (de)
JP (1) JP3815966B2 (de)
KR (1) KR100494347B1 (de)
CN (1) CN1146566C (de)
AR (1) AR017796A1 (de)
AT (1) ATE248169T1 (de)
AU (1) AU744014B2 (de)
BR (1) BR9815140A (de)
CA (1) CA2312885C (de)
DE (1) DE69817611T2 (de)
DK (1) DK1036794T3 (de)
ES (1) ES2205574T3 (de)
HU (1) HUP0004422A3 (de)
ID (1) ID24929A (de)
IL (1) IL135920A0 (de)
NO (1) NO20002835L (de)
NZ (1) NZ504457A (de)
PL (1) PL191489B1 (de)
PT (1) PT1036794E (de)
RU (1) RU2223272C2 (de)
SK (1) SK285703B6 (de)
TR (1) TR200001600T2 (de)
TW (1) TW502034B (de)
WO (1) WO1999028320A1 (de)
ZA (1) ZA9810490B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
EP1219608A4 (de) * 1999-09-27 2003-01-08 Ono Pharmaceutical Co Pyrimidinderivate, verfahren zur herstellung der derivate und sie als aktiven bestandteil enthaltende medikamente
PL363870A1 (en) * 2000-07-31 2004-11-29 Dainippon Pharmaceutical Co, Ltd. Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
EP1663994B1 (de) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydrochinazolin-verbindungen als inhibitoren von spannungsabhängigen ionenkanälen
US20070191447A1 (en) * 2004-02-23 2007-08-16 Toru Kodo Novel heterocyclic compound
EP1734820A4 (de) * 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrazine, imidazopyridine und imidazopyrimidine als crf1-rezeptorliganden
FR2870239B1 (fr) 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
KR20080013886A (ko) * 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
JP2009529541A (ja) * 2006-03-09 2009-08-20 ファーマコピア インコーポレーテッド 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
WO2008043031A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063141A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2078016B1 (de) 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
KR101820541B1 (ko) * 2009-09-09 2018-02-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 8-옥소디히드로퓨린 유도체
ES2751705T3 (es) 2009-10-26 2020-04-01 Signal Pharm Llc Métodos de síntesis y purificación de compuestos heteroarilo
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
EP2718464A1 (de) 2011-06-06 2014-04-16 Imperial Innovations Limited Verfahren zur vorhersage der bindungsaffinität von tspo-kontrastmitteln an tspo
MX384385B (es) 2011-10-19 2025-03-14 Signal Pharm Llc Tratamiento del cancer con inhibidores de tor cinasa
JP6076370B2 (ja) 2011-12-02 2017-02-08 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR094494A1 (es) 2013-01-16 2015-08-05 Signal Pharm Llc Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986319A1 (de) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Kombinationstherapie mit einem torkinaseinhibitor und n-(3-(5-fluor-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamid zur behandlung von krebs
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
SG11201508223YA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (de) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmazeutische formulierungen von 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)-pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR102708936B1 (ko) 2015-11-20 2024-09-25 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 억제제로서의 퓨리논
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
JP4667543B2 (ja) * 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
US6211195B1 (en) * 1997-04-22 2001-04-03 Neurocrine Biosciences, Inc. CRF antagonistic thiophenopyridines
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
NO20002835D0 (no) 2000-06-02
ZA9810490B (en) 1999-05-20
WO1999028320A1 (en) 1999-06-10
AR017796A1 (es) 2001-10-24
SK285703B6 (sk) 2007-06-07
AU744014B2 (en) 2002-02-14
JP3815966B2 (ja) 2006-08-30
HUP0004422A3 (en) 2001-10-29
NO20002835L (no) 2000-07-24
CA2312885C (en) 2008-01-29
DE69817611T2 (de) 2004-02-26
RU2223272C2 (ru) 2004-02-10
TW502034B (en) 2002-09-11
EP1036794A4 (de) 2001-12-12
KR100494347B1 (ko) 2005-06-13
EP1036794A1 (de) 2000-09-20
ATE248169T1 (de) 2003-09-15
BR9815140A (pt) 2000-10-10
HK1028769A1 (en) 2001-03-02
HUP0004422A2 (hu) 2001-04-28
PL191489B1 (pl) 2006-05-31
EP1036794B1 (de) 2003-08-27
DK1036794T3 (da) 2003-12-22
TR200001600T2 (tr) 2000-11-21
PL340925A1 (en) 2001-03-12
CN1146566C (zh) 2004-04-21
AU1260499A (en) 1999-06-16
KR20010032686A (ko) 2001-04-25
ES2205574T3 (es) 2004-05-01
CN1284076A (zh) 2001-02-14
SK7972000A3 (en) 2001-03-12
CA2312885A1 (en) 1999-06-10
NZ504457A (en) 2001-12-21
IL135920A0 (en) 2001-05-20
PT1036794E (pt) 2003-11-28
ID24929A (id) 2000-08-31
US6372740B1 (en) 2002-04-16

Similar Documents

Publication Publication Date Title
DE69817611D1 (de) 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate
ATE299148T1 (de) Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
ATE243682T1 (de) Heterozyklisch substituierte biphenylamid derivate, deren herstellung und deren verwendung als fungizide
DE69627411D1 (de) Triazinderivate, ihre Herstellung und Verwendung
DE69916828D1 (de) Pyrazoline, ihre herstellung und verwendung als medikamente
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
DE69821623D1 (de) Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament
ATE239712T1 (de) Disubstituierte bicyclische heterocyclen, ihre herstellung und ihre verwendung als arzneimittel
ATE239693T1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
ATE302604T1 (de) Thienylazolylalkoxyethanamine, deren herstellung und deren verwendung als medikamente
DE59907961D1 (de) Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
DE10084441T1 (de) Koalinton-Pigmente, ihre Herstellung und Verwendung
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE60001307D1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
DE69625857D1 (de) Siliconderivate, ihre Herstellung und Verwendung
DE59802590D1 (de) Cyclische Cedren-Acetale, ihre Herstellung und ihre Verwendung
ATE439439T1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
DE59710272D1 (de) Neue alpha-hydroxysäurederivate, ihre herstellung und verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69521595D1 (de) Optisch-aktives Benzothiepin-Derivate, ihre Herstellung und Verwendung
DE60009155D1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
ATE251170T1 (de) Titanverbindungen, deren herstellung und verwendung
DE59802922D1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
ATE268760T1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., OSAKA, JP

8339 Ceased/non-payment of the annual fee